Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.32 |
| ▸ | JAK1 | P23458 | 5/20 | 0.32 |
| ▸ | JAK3 | P52333 | 4/20 | 0.32 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | BTK | Q06187 | 3/20 | 0.31 |
| ▸ | IGF1R | P08069 | 2/20 | 0.31 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CD38 | P28907 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9918519 | 0.89 | IGF1R (0.33) | SYKKCNH2JAK1JAK3JAK2 | |
| SCHEMBL9918530 | 0.75 | LRRK2 (0.38) | SYKKCNH2JAK1JAK3JAK2 | |
| SCHEMBL9918521 | 0.74 | IGF1R (0.34) | JAK1JAK3JAK2IGF1RMAPK8 | |
| SCHEMBL9918526 | 0.73 | LRRK2 (0.43) | SYKKCNH2IGF1R | |
| SCHEMBL9918529 | 0.72 | JAK1 (0.34) | SYKJAK1JAK3JAK2 | |
| SCHEMBL9920226 | 0.69 | JAK1 (0.48) | JAK1JAK3JAK2 | |
| SCHEMBL12832928 | 0.69 | LRRK2 (0.45) | JAK1JAK3JAK2BTK | |
| SCHEMBL9918546 | 0.66 | SYK (0.33) | SYKKCNH2JAK2 | |
| SCHEMBL12832698 | 0.66 | IKBKB (0.39) | JAK1JAK3JAK2BTK | |
| SCHEMBL12832699 | 0.66 | JAK2 (0.34) | SYKKCNH2JAK1JAK3JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | SYK 87/4885KCNH2 1267/4885PTGS2 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.